Current Oncology | Free Full-Text | Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink
Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice | PLOS ONE
Frontiers | Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis
Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced/Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy - Tam Binh V Bui, Desirée MT Burgers, Mariette J Agterof, Ewoudt
Progression-free survival for palbociclib plus letrozole by line of... | Download Scientific Diagram
Effectiveness and safety of Palbociclib as first-line treatment in advanced breast cancer - ILAPHAR | Revista de la OFIL
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - ScienceDirect
View PDF
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia - Sun - 2021 - Cancer Medicine - Wiley Online Library
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice | Breast Cancer Research | Full Text
IJMS | Free Full-Text | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Palbociclib–fulvestrant combo yields overall survival gains in advanced breast cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
Final analysis of progression-free survival in the PALOMA-3 study... | Download Scientific Diagram
Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor‑positive and human epidermal growth factor receptor 2‑negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer - Gelmon - 2020 - The Breast Journal -
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: An observational study of the SONABRE Registry - The Lancet Regional Health – Europe
A) Progressionfree survival rate and (B) overall survival rate in... | Download Scientific Diagram
No Clear Survival Benefit for Fulvestrant Versus Letrozole in Combination With Palbociclib for Endocrine-Sensitive Metastatic Breast Cancer
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink
IBRANCE (palbociclib) Pharmacological Properties | Pfizer Medical Information - République française
IBRANCE 75 mg hard capsules - Summary of Product Characteristics (SmPC) - print friendly - (emc)
Ribociclib Improves Survival in Advanced Breast Cancer - NCI
![ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR](https://cdn.koreabiomed.com/news/photo/202206/13831_14394_912.jpg "ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR")